Management of patients with hidradenitis suppurativa during the COVID-19 pandemic.
作者信息
Montero-Vilchez Trinidad, Martinez-Lopez Antonio, Salvador-Rodriguez Luis, Molina-Leyva Alejandro, Arias-Santiago Salvador
机构信息
Department of Dermatology, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Instituto de Investigación Biosanitaria (ibs.Granada), Granada, Spain.
出版信息
Dermatol Ther. 2020 Nov;33(6):e13875. doi: 10.1111/dth.13875. Epub 2020 Jul 7.
Abstract
摘要
相似文献
1
Management of patients with hidradenitis suppurativa during the COVID-19 pandemic.新冠疫情期间化脓性汗腺炎患者的管理
Dermatol Ther. 2020 Nov;33(6):e13875. doi: 10.1111/dth.13875. Epub 2020 Jul 7.
2
Hidradenitis suppurativa perspectives during the COVID-19 pandemic.COVID-19 大流行期间的化脓性汗腺炎展望。
Clin Dermatol. 2023 Sep-Oct;41(5):622-627. doi: 10.1016/j.clindermatol.2023.08.018. Epub 2023 Aug 31.
3
Anti-COVID-19 measurements for hidradenitis suppurativa patients.防治化脓性汗腺炎患者感染 COVID-19 的措施。
Exp Dermatol. 2021 Jun;30 Suppl 1(Suppl 1):18-22. doi: 10.1111/exd.14339.
4
Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy.COVID-19 大流行期间化脓性汗腺炎患者的管理：免疫调节治疗的风险和获益。
Dermatol Ther. 2020 Nov;33(6):e14256. doi: 10.1111/dth.14256. Epub 2020 Sep 14.
5
Hidradenitis suppurativa and adalimumab in the COVID-19 era.新冠疫情时代的化脓性汗腺炎与阿达木单抗
Eur J Dermatol. 2020 Dec 1;30(6):748-749. doi: 10.1684/ejd.2020.3927.
6
Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic.COVID-19大流行期间肿瘤坏死因子-α抑制剂治疗化脓性汗腺炎的影响
J Cutan Med Surg. 2021 Jul-Aug;25(4):446-448. doi: 10.1177/1203475421997058. Epub 2021 Feb 24.
7
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus.一名接受司库奇尤单抗治疗、患有化脓性汗腺炎和系统性红斑狼疮的患者感染了新冠病毒。
Int J Dermatol. 2020 Nov;59(11):1423-1424. doi: 10.1111/ijd.15209. Epub 2020 Sep 23.
8
Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?在新冠疫情期间，化脓性汗腺炎的生物治疗与银屑病的生物治疗有何不同？
J Dermatolog Treat. 2022 Feb;33(1):599. doi: 10.1080/09546634.2020.1771256. Epub 2020 Jun 19.
9
Remote management of hidradenitis suppurativa in a pandemic era of COVID-19.COVID-19大流行时代化脓性汗腺炎的远程管理
Int J Dermatol. 2020 Sep;59(9):e318-e320. doi: 10.1111/ijd.15022. Epub 2020 Jun 23.
10
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa'.化脓性汗腺炎患者在新冠疫苗接种期间的管理：来自意大利南部的经验。评论：“评估化脓性汗腺炎患者接种新冠疫苗的安全性和有效性”
Clin Exp Dermatol. 2022 Nov;47(11):2026-2028. doi: 10.1111/ced.15306. Epub 2022 Aug 4.
引用本文的文献
1
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature.COVID-19 疫苗接种对炎症性皮肤疾病和其他皮肤疾病的影响：已发表文献综述。
Viruses. 2023 Jun 23;15(7):1423. doi: 10.3390/v15071423.
2
Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.新冠疫情期间接受生物制剂治疗的银屑病和化脓性汗腺炎患者的皮肤表现
J Clin Med. 2021 Dec 13;10(24):5841. doi: 10.3390/jcm10245841.
3
Clinical Dermatology and COVID-19 Pandemic: Narrative Review.临床皮肤病学与新冠疫情：叙述性综述
Indian J Dermatol. 2021 May-Jun;66(3):246-255. doi: 10.4103/ijd.ijd_463_21.
本文引用的文献
1
Novel Therapeutic Approaches and Targets for the Treatment of Hidradenitis Suppurativa.用于治疗化脓性汗腺炎的新型治疗方法和靶点。
Curr Pharm Biotechnol. 2021;22(1):59-72. doi: 10.2174/1389201021666200505100556.
2
Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.阿达木单抗在2019冠状病毒病大流行期间用于治疗化脓性汗腺炎：安全性考量
J Am Acad Dermatol. 2020 Jul;83(1):e31. doi: 10.1016/j.jaad.2020.04.030. Epub 2020 Apr 10.
3
Should patients stop their biologic treatment during the COVID-19 pandemic.在新冠疫情期间，患者是否应该停止生物制剂治疗？
J Dermatolog Treat. 2020 Jun;31(4):317-318. doi: 10.1080/09546634.2020.1742438. Epub 2020 Mar 19.
4
Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.新型冠状病毒（COVI-19 或 SARS-CoV-2）诱导促炎细胞因子（IL-1 和 IL-6）和肺部炎症：抗炎策略。
J Biol Regul Homeost Agents. 2020;34(2):327-331. doi: 10.23812/CONTI-E.
5
COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.新型冠状病毒肺炎与银屑病：是时候限制免疫抑制剂的使用了吗？呼吁采取行动。
Dermatol Ther. 2020 Jul;33(4):e13298. doi: 10.1111/dth.13298. Epub 2020 Mar 22.
6
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
7
Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults.美国儿童和成人的化脓性汗腺炎与皮肤和皮肤外感染的相关性。
Br J Dermatol. 2020 Feb;182(2):327-334. doi: 10.1111/bjd.18093. Epub 2019 Jul 25.
8
Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group.化脓性汗腺炎/反向痤疮：治疗优化的实用框架 - HS ALLIANCE 工作组的系统评价和建议。
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31. doi: 10.1111/jdv.15233. Epub 2018 Oct 23.
Zotero 插件